Multidisciplinary Management of Locoregional Recurrent Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Postmastectomy and Regional Nodal Radiation for Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. 23rd May 2020 Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) […]
Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement. 23rd May 2020 The Oncology Grand Rounds series is designed to place original reports published […]
Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. 23rd May 2020 Cancer diagnostics and surgery have been disrupted by the response of healthcare […]
Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Integration of Breast Reconstruction and Postmastectomy Radiotherapy. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Oncoplastic Surgery in the Management of Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Locoregional Management After Neoadjuvant Chemotherapy. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Imaging in Locoregional Management of Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Genetic Factors in the Locoregional Management of Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Multidisciplinary Locoregional Management of Breast Cancer. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
Molecular Predictive and Prognostic Markers in Locoregional Management. 23rd May 2020 Click here to read the full article @ Journal of clinical oncology […]
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. 22nd May 2020 Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with […]
Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? 22nd May 2020 Click here to read the full article @ The Lancet. Oncology
Quest for Clinically Effective RAF Dimer Inhibitors. 21st May 2020 Click here to read the full article @ Journal of clinical oncology […]
Management of Cancer Cachexia: ASCO Guideline. 21st May 2020 To provide evidence-based guidance on the clinical management of cancer cachexia in […]
Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled Trial Setting to National Practice. 19th May 2020 The aim of this study was to examine the external validity of […]
Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy. 19th May 2020 The TRK pathway controls appetite, balance, and pain sensitivity. While these functions […]
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. 19th May 2020 To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior […]
Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis. 19th May 2020 To identify factors associated with chemotherapy-induced vomiting (CIV) control in pediatric patients […]
Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. 19th May 2020 We report here the outcomes and late effects of the Japanese Study […]
Towards greater clarity in the treatment of cholangiocarcinoma. 17th May 2020 Click here to read the full article @ The Lancet. Oncology
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. 17th May 2020 Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with […]
Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. 17th May 2020 Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis […]
Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. 17th May 2020 Alpelisib (α-selective PI3K inhibitor) plus fulvestrant is approved in multiple countries for […]
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. 16th May 2020 Click here to read the full article @ Annals of oncology : […]
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. 15th May 2020 To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin […]
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. 14th May 2020 The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety […]
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. 14th May 2020 Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell […]
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children’s Oncology Group. 14th May 2020 Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). […]
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. 12th May 2020 In men with localized prostate cancer, the addition of androgen-deprivation therapy (ADT) […]
Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer. 11th May 2020 Click here to read the full article @ The Lancet. Oncology
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. 11th May 2020 Anti-PD-1 antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately […]
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. 11th May 2020 Approximately 25% of all patients with non-small-cell lung cancer present with resectable […]
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. 11th May 2020 Gastroesophageal adenocarcinomas (GEA) are heterogeneous cancers where immune checkpoint inhibitors (ICI) have […]
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. 11th May 2020 In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has […]
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. 11th May 2020 Primary tumor location (PTL) is being adopted by clinicians to guide treatment […]
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. 7th May 2020 The impact of rituximab on health-related quality of life (HRQoL) in primary […]
PD-1 Blockade in Anaplastic Thyroid Carcinoma. 5th May 2020 Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal […]
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. 5th May 2020 There is no consensus on the best choice of an alternative donor […]
Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. 5th May 2020 Nonadherence to aromatase inhibitors (AIs) for breast cancer is common and increases […]
The increasing value of eHealth in the delivery of patient-centred cancer care. 4th May 2020 The increasing use of eHealth has ushered in a new era of […]
Outcome measures in multimodal rectal cancer trials. 4th May 2020 There is a large variability regarding the definition and choice of primary […]
COVID-19: The European institute of oncology as a “hub” centre for breast cancer surgery during the pandemic in Milan (Lombardy region, northern Italy) – A screenshot of the first month. 4th May 2020 Click here to read the full article @ European journal of surgical […]
Management of Gynaecological oncology diseases during COVID-19 global pandemic. 4th May 2020 Click here to read the full article @ European journal of surgical […]
Managing the COVID-19 Pandemic as a National Radiation Oncology Centre in Singapore. 4th May 2020 COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared […]
Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany? 4th May 2020 The coronavirus disease 2019 (COVID-19) pandemic is challenging for physicians treating patients […]
Interventional oncology at the time of COVID-19 pandemic: Problems and solutions. 4th May 2020 The COVID-19 pandemic has deeply impacted the activity of interventional oncology in […]
Cutaneous metastasis of renal cell carcinoma. 4th May 2020 Click here to read the full article @ The Lancet. Oncology
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. 4th May 2020 Click here to read the full article @ The Lancet. Oncology
The global imperative to make cancer medications affordable. 4th May 2020 Click here to read the full article @ The Lancet. Oncology
Cancer care for refugees: time to invest in people and systems. 4th May 2020 Click here to read the full article @ The Lancet. Oncology
The economic burden of cancer care for Syrian refugees: a population-based modelling study. 4th May 2020 Cancer represents a substantial health burden for refugees and host countries. However, […]
